Cincinnati Children's Hospital Medical Center
Latest From Cincinnati Children's Hospital Medical Center
Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma
Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.
In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.
Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.
Believing biomedical research at Duke is “under fished” compared to the ponds in San Francisco and Boston, Duke’s institutional CRO looks to provide clinical trial design and other services to help tech transfer along. Plus, recent tech transfer deals include AbbVie, Calimmune and China’s Yisheng.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.